Factor H and Neisserial pathogenesis

Vaccine

Volumn 26, Issue SUPPL. 8, 2008, Pages

  Welsch, Jo Anne ^a   Ram, Sanjay ^b  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Complement; Factor H; Factor H binding protein; Neisseria gonorrhoeae; Neisseria meningitidis; Serum resistance

Indexed keywords

BINDING PROTEIN; COMPLEMENT COMPONENT C4B; COMPLEMENT FACTOR H; FACTOR H BINDING PROTEIN; LIPOOLIGOSACCHARIDE; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY; PORIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; COMPLEMENT DEFICIENCY; COMPLEMENT EVASION; COMPLEMENT INHIBITION; DELETION MUTANT; FLOW CYTOMETRY; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MENINGOCOCCOSIS; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; NONHUMAN; OPSONIZATION; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; SERUM CHARACTERISTICS; SERUM RESISTANCE; SIALYLATION; SPECIES DIFFERENCE; WILD TYPE;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT FACTOR H; COMPLEMENT SYSTEM PROTEINS; GONORRHEA; HUMANS; LIGANDS; LIPOPOLYSACCHARIDES; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; N-ACETYLNEURAMINIC ACID; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; SPECIES SPECIFICITY;

EID: 57649220619     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.060     Document Type: Article

References (59)

1. Pangburn M.K., Schreiber R.D., and Muller-Eberhard H.J. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med 146 1 (1977) 257-270
2. Sim R.B., and DiScipio R.G. Purification and structural studies on the complement-system control protein beta 1H (Factor H). Biochem J 205 2 (1982) 285-293
3. Whaley K., and Ruddy S. Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med 144 5 (1976) 1147-1163
4. Fearon D.T. Regulation by membrane sialic acid of β1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci USA 75 (1978) 1971-1975
5. Kazatchkine M.D., Fearon D.T., and Austen K.F. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol 122 1 (1979) 75-81
6. Ripoche J., Day A.J., Harris T.J., and Sim R.B. The complete amino acid sequence of human complement factor H. Biochem J 249 2 (1988) 593-602
7. Gordon D.L., Kaufman R.M., Blackmore T.K., Kwong J., and Lublin D.M. Identification of complement regulatory domains in human factor H. J Immunol 155 1 (1995) 348-356
8. Jokiranta T.S., Cheng Z.Z., Seeberger H., Jozsi M., Heinen S., Noris M., et al. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol 167 4 (2005) 1173-1181
9. Ormsby R.J., Jokiranta T.S., Duthy T.G., Griggs K.M., Sadlon T.A., Giannakis E., et al. Localization of the third heparin-binding site in the human complement regulator factor H1. Mol Immunol 43 10 (2006) 1624-1632
10. Schmidt C.Q., Herbert A.P., Kavanagh D., Gandy C., Fenton C.J., Blaum B.S., et al. A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol 181 4 (2008) 2610-2619
11. Wurzner R. Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Mol Immunol 36 4-5 (1999) 249-260
12. Kraiczy P., and Wurzner R. Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol Immunol 43 1-2 (2006) 31-44
13. Figueroa J., Andreoni J., and Densen P. Complement deficiency states and meningococcal disease. Immunol Res 12 3 (1993) 295-311
14. Ross S.C., and Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 63 5 (1984) 243-273
15. Fijen C.A., Kuijper E.J., te Bulte M.T., Daha M.R., and Dankert J. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 28 1 (1999) 98-105
16. Nagata M., Hara T., Aoki T., Mizuno Y., Akeda H., Inaba S., et al. Inherited deficiency of ninth component of complement: an increased risk of meningococcal meningitis. J Pediatr 114 2 (1989) 260-264
17. Densen P., Weiler J.M., Griffiss J.M., and Hoffmann L.G. Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination. N Engl J Med 316 15 (1987) 922-926
18. Sjoholm A.G., Braconier J.H., and Soderstrom C. Properdin deficiency in a family with fulminant meningococcal infections. Clin Exp Immunol 50 2 (1982) 291-297
19. Braconier J.H., Sjoholm A.G., and Soderstrom C. Fulminant meningococcal infections in a family with inherited deficiency of properdin. Scand J Infect Dis 15 4 (1983) 339-345
20. Soderstrom C., Sjoholm A.G., Svensson R., and Ostenson S. Another Swedish family with complete properdin deficiency: association with fulminant meningococcal disease in one male family member. Scand J Infect Dis 21 3 (1989) 259-265
21. Biesma D.H., Hannema A.J., van Velzen-Blad H., Mulder L., van Zwieten R., Kluijt I., et al. A family with complement factor D deficiency. J Clin Invest 108 2 (2001) 233-240
22. Brandtzaeg P., Mollnes T.E., and Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 160 1 (1989) 58-65
23. Tesh V.L., Duncan Jr. R.L., and Morrison D.C. The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing. J Immunol 137 4 (1986) 1329-1335
24. O'Hara A.M., Moran A.P., Wurzner R., and Orren A. Complement-mediated lipopolysaccharide release and outer membrane damage in Escherichia coli J5: requirement for C9. Immunology 102 3 (2001) 365-372
25. Lehner P.J., Davies K.A., Walport M.J., Cope A.P., Wurzner R., Orren A., et al. Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release. Lancet 340 8832 (1992) 1379-1381
26. Fijen C.A., Kuijper E.J., Hannema A.J., Sjoholm A.G., and van Putten J.P. Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups [see comments]. Lancet 2 8663 (1989) 585-588
27. Fijen C.A., Kuijper E.J., Tjia H.G., Daha M.R., and Dankert J. Complement deficiency predisposes for meningitis due to nongroupable meningococci and Neisseria-related bacteria. Clin Infect Dis 18 5 (1994) 780-784
28. Orren A., Caugant D.A., Fijen C.A., Dankert J., van Schalkwyk E.J., Poolman J.T., et al. Characterization of strains of Neisseria meningitidis recovered from complement-sufficient and complement-deficient patients in the Western Cape Province, South Africa. J Clin Microbiol 32 9 (1994) 2185-2191
29. Fearon D.T., and Austen K.F. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med 142 4 (1975) 856-863
30. Pickering M.C., and Cook H.T. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 151 2 (2008) 210-230
31. Haralambous E., Dolly S.O., Hibberd M.L., Litt D.J., Udalova I.A., O'Dwyer C., et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis 38 9 (2006) 764-771
32. Ram S., Sharma A.K., Simpson S.D., Gulati S., McQuillen D.P., Pangburn M.K., et al. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med 187 5 (1998) 743-752
33. Gulati S., Cox A., Lewis L.A., Michael F.S., Li J., Boden R., et al. Enhanced factor H binding to sialylated gonococci is restricted to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications for serum resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in gonococci. Infect Immun 73 11 (2005) 7390-7397
34. Ram S., McQuillen D.P., Gulati S., Elkins C., Pangburn M.K., and Rice P.A. Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J Exp Med 188 4 (1998) 671-680
35. Schoolnik G.K., Buchanan T.M., and Holmes K.K. Gonococci causing disseminated gonococcal infection are resistant to the bactericidal action of normal human sera. J Clin Invest 58 5 (1976) 1163-1173
36. O'Brien J.P., Goldenberg D.L., and Rice P.A. Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine 62 (1983) 395-406
37. Madico G., Ngampasutadol J., Gulati S., Vogel U., Rice P.A., Ram S., and Factor H. Binding and function in sialylated pathogenic Neisseriae is Influenced by gonococcal, but not meningococcal. Porin. J Immunol 178 7 (2007) 4489-4497
38. Ram S., Mackinnon F.G., Gulati S., McQuillen D.P., Vogel U., Frosch M., et al. The contrasting mechanisms of serum resistance of Neisseria gonorrhoeae and Neisseria meningitidis. Mol Immunol 4-5 2 (1999) 915-928
39. Estabrook M.M., Jack D.L., Klein N.J., and Jarvis G.A. Mannose-binding lectin binds to two major outer membrane proteins, opacity protein and porin, of Neisseria meningitidis. J Immunol 172 6 (2004) 3784-3792
40. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177 1 (2006) 501-510
41. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.H., Sim R.B., et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 176 12 (2006) 7566-7575
42. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197 6 (2003) 789-799
43. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72 4 (2004) 2088-2100
44. Welsch J.A., Ram S., Koeberling O., and Granoff D.M. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 197 7 (2008) 1053-1061
45. Geoffroy M.C., Floquet S., Metais A., Nassif X., and Pelicic V. Large-scale analysis of the meningococcus genome by gene disruption: resistance to complement-mediated lysis. Genome Res 13 3 (2003) 391-398
46. Mackinnon F.G., Borrow R., Gorringe A.R., Fox A.J., Jones D.M., and Robinson A. Demonstration of lipooligosaccharide immunotype and capsule as virulence factors for Neisseria meningitidis using an infant mouse intranasal infection model. Microb Pathog 15 5 (1993) 359-366
47. Vogel U., and Frosch M. Mechanisms of neisserial serum resistance. Mol Microbiol 32 6 (1999) 1133-1139
48. Vogel U., Hammerschmidt S., and Frosch M. Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitidis serogroup B are prerequisites for virulence of meningococci in the infant rat. Med Microbiol Immunol (Berl) 185 2 (1996) 81-87
49. Vogel U., Weinberger A., Frank R., Muller A., Kohl J., Atkinson J.P., et al. Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis. Infect Immun 65 10 (1997) 4022-4029
50. Beernink P.T., Welsch J.A., Bar-Lev M., Koeberling O., Comanducci M., and Granoff D.M. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein. Infect Immun 76 9 (2008) 4232-4240
51. Welsch J.A., Rossi R., Comanducci M., and Granoff D.M. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 172 9 (2004) 5606-5615
52. Ngampasutadol J., Ram S., Blom A.M., Jarva H., Jerse A.E., Lien E., et al. Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad Sci USA 102 47 (2005) 17142-17147
53. Welsch J.A., Ram S., and Granoff D.M. Implications of human species-specific binding of complement factor H to Neisseria meningitidis for assaying functional activity of vaccine-induced serum antibodies using non-human complement. In: van Alphen L., van der Ley P., and van den Dobbelsteen G. (Eds). 16th International Pathogenic Neisseria Conference. Rotterdam (2008) 152-153
54. Santos G.F., Deck R.R., Donnelly J., Blackwelder W., and Granoff D.M. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 8 3 (2001) 616-623
55. Zollinger W.D., and Mandrell R.E. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun 40 1 (1983) 257-264
56. Hou V.C., Koeberling O., Welsch J.A., and Granoff D.M. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 192 4 (2005) 580-590
57. Saukkonen K. Experimental meningococcal meningitis in the infant rat. Microb Pathog 4 3 (1988) 203-211
58. Toropainen M., Kayhty H., Saarinen L., Rosenqvist E., Hoiby E.A., Wedege E., et al. The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci. Vaccine 17 20-21 (1999) 2677-2689
59. Toropainen M., Saarinen L., Wedege E., Bolstad K., Makela P.H., and Kayhty H. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines. Vaccine 23 40 (2005) 4821-4833